Advertisement

Topics

[News] Bosutinib more effective than imatinib in CML

23:08 EST 9 Nov 2017 | The Lancet

Bosutinib might be a more effective first-line therapy than imatinib for patients with newly diagnosed chronic myeloid leukaemia (CML), according to results from the randomised, phase 3 BFORE trial.

Original Article: [News] Bosutinib more effective than imatinib in CML

NEXT ARTICLE

More From BioPortfolio on "[News] Bosutinib more effective than imatinib in CML"

Advertisement
Quick Search
Advertisement
Advertisement